Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: October 2017
Report Code: LS11287
Available Format:
Pages: 113

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation


Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, and is responsible for cell proliferation, survival, invasion, metastasis, angiogenesis, and inflammation. Therefore, the development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation. Although, many different NF-kB inhibitors are reported, still there are no marketed drugs available.

NF-kB inhibitors act on NF-kB signaling at different levels, including at upstream of I-kB kinase (IKK) (for instance, at a receptor or adaptor level), directly at the IKK complex or I-kB phosphorylation, during ubiquitination or proteasomal degradation of I-kB, during nuclear translocation of NF-kB, NF-kB DNA binding, and NF-kB-directed gene transactivation. The level at which the drug candidate inhibits the NF-kB signaling pathway is simportant for better efficacy and helps to reduce adverse events.



Many drugs have been identified that indirectly act as NF-kB inhibitors, including Fluvastatin, Carbocysteine, Ritonavir, Rapamycin, Raloxifene, and others. Their indirect targeting can be the result of crosstalk between their primary targets with the NF-kB signaling pathway.

Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies by targeting NF-kB which can be effective in various indications including cancer and chronic inflammation treatment. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.

Pipeline Analysis

As of September 2017, the NF-kB inhibitors therapeutics pipeline comprises of approximately 17 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 6000

Pre-Purchase Enquiry